HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Mechanism of action == DT56a has been described in scientific literature as a selective estrogen receptor modulator (SERM)-like compound. Experimental studies have suggested that DT56a may exert agonistic effects on estrogen receptors in bone and brain tissues, while demonstrating limited activity in uterine and breast tissues. Several studies have investigated DT56a in relation to menopausal symptoms and bone health. In vitro studies have also reported stimulation of osteoblast activity in cultured human bone cells. Published studies have additionally suggested that DT56a does not significantly affect circulating hormone levels or blood coagulation parameters.
In April 2009, Kardashian and her sister Kourtney announced that they were contracted to star in a spin-off that would follow their move to launch a D-A-S-H store in Miami, Florida. The series, Kourtney and Khloé Take Miami, debuted on E! on August 16, 2009. Starting May 29, 2009, Kardashian joined Miami Top 40 Mainstream outlet WHYI for a weekly four-hour talk/entertainment program, co-hosted by 106 & Park's Terrence J. Khloé and her sisters Kim and Kourtney made a cameo appearance in the Season 3 premiere of the series 90210. Kardashian made an appearance in episodes 2, 4, and 8 of Kourtney and Kim Take New York, which premiered in January 2011. On April 10, 2011, Khloé & Lamar, Kardashian's own show with her then-husband, Lamar Odom, debuted. Kardashian participated in the second season of The Celebrity Apprentice, finishing 10th of 16 candidates by being fired by Donald Trump. It was reported she was fired because of her previous arrest for a DUI. In June 2009, Khloé and her sisters teamed up with the Natural Products Association to create a teeth whitening pen called Idol White. Kardashian appeared in one of PETA's "I'd Rather Go Naked Than Wear Fur" campaigns. The three sisters released a jewelry line in March 2010. In the spring of 2010, the sisters released a clothing line for Bebe. Bebe announced they were dropping the line in December 2010. In September 2010, Kardashian and her sisters released another clothing line, K-Dash on QVC. Kardashian and her sisters marketed a fake tan product, released in 2010 and called Kardashian Glamour Tan.
== History == Malacidins were discovered by researchers at Rockefeller University, led by Brad Hover and Sean Brady. The group had been looking into antibiotics related to daptomycin and their calcium-dependent nature, but determined that it would be impractical to culture variations in lab conditions. Instead, the team used a genetics approach that was more scalable. They focused on searching for novel biosynthetic gene clusters (BGCs) – genes that are usually expressed together, that bacteria use to make secondary metabolites. To do this, they extracted DNA from around 2,000 soil samples to build metagenomic libraries that captured the genetic diversity of the environmental microbiome. They then designed degenerate primers to amplify genes likely to be similar to the BGC that make daptomycin by using a polymerase chain reaction (PCR) procedure, sequenced the amplified genes, and then used metagenomics to confirm that these genes were indeed likely to be the kind of BGCs they sought. One of the novel BGCs they found was present in around 19% of the screened soil samples but not readily found in cultured microbial collections, so they took that BGC, put it into other host bacteria, and then isolated and analyzed the secondary metabolites. The work was published in Nature Microbiology in February 2018.
Prolactin also self-regulates through a counter-current flow in the hypophyseal pituitary portal system, which triggers the release of hypothalamic dopamine. This process also inhibits the pulsatile secretion of gonadotropin-releasing hormone (GnRH), thereby negatively influencing the secretion of pituitary hormones that regulate gonadal function. Estrogen promotes the growth of pituitary lactotroph cells, particularly during pregnancy. However, lactation is hindered by the elevated levels of estrogen and progesterone during this period. The rapid decline in estrogen and progesterone after childbirth enables lactation to begin. While breastfeeding, prolactin suppresses gonadotropin secretion, potentially delaying ovulation. Ovulation may resume before the return of menstruation during this time. Although hyperprolactinemia can result from normal physiological changes during pregnancy and breastfeeding, it can also be caused by other etiologies. For example, high prolactin levels could result from diseases affecting the hypothalamus and pituitary gland. Other organs, such as the liver and kidneys, could affect prolactin clearance and consequently, prolactin levels in the serum. The disruption of prolactin regulation could also be attributed to external sources such as medications. In the general population, the prevalence of hyperprolactinemia is 0.4%. The prevalence increases to as high as 17% in women with reproductive diseases, such as polyendocrine metabolic ovarian syndrome.
Sources: en.wikipedia.org
=== Jackie Harris === Marjorie Jacqueline "Jackie" Harris Goldufski is played by Laurie Metcalf. Jackie is Roseanne's younger sister by three years. She is a neurotic but a loving, devoted aunt to her nieces and nephews, and later mother to Andy. Jackie is an intelligent, warm, highly sensitive underachiever with chronic low self-esteem. Roseanne seems to be in charge of Jackie's life, which frequently causes conflict between the two sisters; however, Jackie sometimes enjoys having Roseanne mother her, especially when she feels vulnerable. Like Roseanne, Jackie's relationship with their mother is strained, chafing under Bev's constant criticism and disapproval of her life choices. She is closer to her father, but as his past abusive behavior is revealed in later seasons, Jackie is shown as having coped by using selective denial or justifying his behavior. Jackie's character becomes more animated and colorful as the series progresses. Jackie holds numerous jobs: working in the Wellman Plastics factory for several years until the walkout, then becoming a police officer until being injured on the job, then is a truck driver before finally opening the Lanford Lunch Box with Roseanne and Nancy, and also mother Bev as a fourth partner. In Season 10, Jackie is now a life coach. In The Conners, Jackie, along with Becky, revives the old Lanford Lunch Box when the previous restaurant occupying the space closes, then struggles to keep it afloat during the COVID pandemic, showing her adaptability and perseverance. Jackie often comes up with off-the-wall ideas, but many actually work.
=== Parkinson's disease === Mesocarb, has been under development for the treatment of Parkinson's disease since 2016. As of February 2023, it is in phase 1 clinical trials for this indication. However, no recent development has been reported. Mesocarb's active enantiomer armesocarb is also under development.
In 2005, ten countries accounted for the majority of the world's concentrated uranium oxides: Canada (27.9%), Australia (22.8%), Kazakhstan (10.5%), Russia (8.0%), Namibia (7.5%), Niger (7.4%), Uzbekistan (5.5%), the United States (2.5%), Argentina (2.1%) and Ukraine (1.9%). In 2008, Kazakhstan was forecast to increase production and become the world's largest supplier of uranium by 2009; Kazakhstan has dominated the world's uranium market since 2010. In 2021, its share was 45.1%, followed by Namibia (11.9%), Canada (9.7%), Australia (8.7%), Uzbekistan (7.2%), Niger (4.7%), Russia (5.5%), China (3.9%), India (1.3%), Ukraine (0.9%), and South Africa (0.8%), with a world total production of 48,332 tonnes. Most uranium was produced not by conventional underground mining of ores (29% of production), but by in-situ leaching (66%). In the late 1960s, UN geologists discovered major uranium deposits and other rare mineral reserves in Somalia. The find was the largest of its kind, with industry experts estimating the deposits at over 25% of the world's then known uranium reserves of 800,000 tons. The ultimate available supply is believed to be sufficient for at least the next 85 years, though some studies indicate underinvestment in the late twentieth century may produce supply problems in the 21st century. Uranium deposits seem to be log-normal distributed. There is a 300-fold increase in the amount of uranium recoverable for each tenfold decrease in ore grade. In other words, there is little high grade ore and proportionately much more low grade ore available.
=== Drug delivery platforms === In therapeutics, synthetic biology has achieved significant advancements in altering and simplifying the therapeutics scope in a relatively short period of time. In fact, new therapeutic platforms, from the discovery of disease mechanisms and drug targets to the manufacture and transport of small molecules, are made possible by the logical and model-guided design construction of biological components. Synthetic biology devices have been designed to act as therapies in therapeutic treatment. It is possible to control complete created viruses and organisms to target particular pathogens and diseased pathways. Thus, in two independent studies 91,92, researchers utilised genetically modified bacteriophages to fight antibiotic-resistant bacteria by giving them genetic features that specifically target and hinder bacterial defences against antibiotic activity. In the therapy of cancer, since conventional medicines frequently indiscriminately target tumours and normal tissues, artificially created viruses and organisms that can identify and connect their therapeutic action to pathological signals may be helpful. For example, p53 pathway activity in human cells was put into adenoviruses to control how they replicated.
Frank Furedi (born 1947) is a Hungarian Jewish British Canadian academic known for work on sociology of fear, education, therapy culture, paranoid parenting and sociology of knowledge; in 1970s, was member of International Socialists (IS); later formed the Revolutionary Communist Group, and then broke from that to form Revolutionary Communist Tendency, refounded as the Revolutionary Communist Party in 1978; RCP was distinguished by its contrarianism; among its positions were support for IRA and Saddam Hussein Furedi is now associated with the RCP's successor, the web site Spiked Online. Neil Gaiman fantasy writer Uri Geller (Hebrew: אורי גלר; born 20 December 1946 in British Mandate of Palestine Mandatory Palestine (now Israel), of Hungarian Jewish ancestry, is an Israeli-British illusionist, magician, television personality, self-proclaimed psychic and author of over ten books, both fiction and non-fiction. Ernest Gellner social anthropologist, scholar of nationalism and identity, of Austrian Jewish and Czech Jewish origin. Adele Geras, (née Weston; born 15 March 1944) FRSL is an English writer for young children, teens and adults. She has written more than 95 books for children, young adults, and adults.
Sources: en.wikipedia.org
== Tissue and subcellular distribution == Galectin-7 is found both intracellularly and extracellularly. It is secreted via a non-classical, endoplasmic reticulum–Golgi–independent pathway and can form galectin–glycan lattices by clustering on cell-surface receptors. It is also present in primary cilia of epithelial cell types such as those of the airway and kidney.
== Fourth- and fifth-hand smoke == More controversially, the related concepts of fourth-hand smoke and even fifth-hand smoke have also been proposed as well to refer to further orders of theoretical contamination from tobacco smoke.
Beekeeping and Sustainable Livelihoods (2004), Food and Agriculture Organization of the United Nations "Honey" . The New Student's Reference Work . 1914. Dubner, Stephen J.; Levitt, Steve (10 April 2026). "Beeconomics 101". Freakonomics. Episode 670. On the bee, honey, and pollination industry in the United States.
Since 1947, the Doomsday Clock of the Bulletin of the Atomic Scientists has visualized how close the world is to a nuclear war. The Doomsday Clock reached a high point in 1953, when the Clock was set to two minutes until midnight after the U.S. and the Soviet Union began testing hydrogen bombs, and in 2018, following the failure of world leaders to address tensions relating to nuclear weapons and climate change issues. Since 2026, the Clock has been set at 85 seconds to midnight, the closest it has ever been.
Guillemin and Schally were awarded the Nobel Prize in Physiology and Medicine in 1977 for their contributions to understanding "the peptide hormone production of the brain". In 1952, Andor Szentivanyi, of the University of South Florida, and Geza Filipp wrote the world's first research paper showing how neural control of immunity takes place through the hypothalamus.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.